Suicidality and divalproex sodium: analysis of controlled studies in multiple indications
2011

Divalproex Sodium and Suicidality: A Meta-Analysis

Sample size: 2319 publication 10 minutes Evidence: moderate

Author Information

Author(s): Laura Redden, Yili Pritchett, Weining Robieson, Xenia Kovacs, Mary Garofalo, Katherine Tracy, Mario Saltarelli

Primary Institution: Abbott, Abbott Park, IL, USA

Hypothesis

Does divalproex sodium increase the risk of suicidality compared to placebo?

Conclusion

Divalproex sodium does not appear to increase the risk of suicide-related adverse events relative to placebo.

Supporting Evidence

  • 11 subjects taking divalproex sodium experienced suicidality events, compared to 9 subjects taking placebo.
  • The overall estimated odds ratio for suicidal behavior or ideation was 0.72.
  • Statistical analyses were conducted using methods similar to those reported by the FDA.

Takeaway

This study looked at whether a medication called divalproex sodium makes people more likely to think about or attempt suicide. It found that it doesn't seem to increase that risk compared to a placebo.

Methodology

The study analyzed data from 13 placebo-controlled studies and 1 low-dose controlled study, using the Columbia Classification Algorithm of Suicide Assessment to identify suicidality events.

Potential Biases

Potential bias due to the retrospective analysis and the variability in study designs and populations.

Limitations

The study's retrospective nature may have led to ascertainment bias, and the smaller dataset may not detect uncommon events.

Participant Demographics

The mean age was 44 years, with 83% of participants being Caucasian.

Statistical Information

P-Value

0.72

Confidence Interval

95% CI 0.29 to 1.84

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1744-859X-10-1

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication